low - Oncology drug demand is largely non-discretionary and driven by disease incidence rather than economic conditions. DLBCL patients requiring third-line therapy will seek treatment regardless of GDP growth. However, hospital budget constraints during recessions could marginally impact purchasing patterns, and payer reimbursement negotiations may intensify during economic downturns.

Rising interest rates negatively impact ADC Therapeutics through multiple channels: higher discount rates compress the present value of distant future cash flows (critical for pre-profitable biotech), increase the cost of any future debt financing, and make risk-free alternatives more attractive to growth-oriented investors. The company's negative operating cash flow means it may need to access capital markets, where higher rates increase dilution risk. Additionally, rising rates typically trigger rotation away from speculative growth stocks toward value and income-generating assets.

growth - The stock attracts speculative biotech investors focused on clinical catalyst-driven appreciation rather than fundamentals. With 146% one-year return despite negative cash flow, the investor base consists primarily of momentum traders, biotech-specialized hedge funds, and retail investors betting on pipeline success or acquisition potential. The negative earnings and minimal revenue base preclude value investors, while the lack of dividends and high volatility deter income-focused or conservative investors. The investment thesis depends entirely on successful clinical development and commercial execution rather than current financial performance.